Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis Panel. N01-BC-27012-74: Early Phase Clinical Trial to Evaluate Safety and Immunogenicity of Human Papilomavirus VLP Base Vacines.
Date: August 29, 2002.
Time: 12 PM to 3 PM.
Agenda: To review and evaluate contract proposals.
Place: 6116 Executive Boulevard, 8th Floor, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Thomas M. Vollberg, PhD, Scientific Review Administrator, Special Review and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institute of Health, 6116 Executive Boulevard, Suite 703/7142, Rockville, MD 20852, 301/594-9582, firstname.lastname@example.org.
This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)Start Signature
Dated: August 19, 2002.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 02-21790 Filed 8-26-02; 8:45 am]
BILLING CODE 4140-01-M